Tarsus Pharmaceuticals, Inc.
TARS
株式のランク
#4560
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
株価
$70.82
最終同期: 2026-10-21
時価総額
$3.31B
変化（1日）
-0.30%
変化（1年）
3.08%
国
US
取引 Tarsus Pharmaceuticals, Inc. (TARS)
カテゴリー
Healthcare
Tarsus Pharmaceuticals, Inc.（TARS）の株価履歴
終値の最高値: $72.26 （2026-10-01）
終値の最安値: $21.51 （2020-10-01）
終値の最安値: $21.51 （2020-10-01）
Tarsus Pharmaceuticals, Inc. の株価履歴（2020 ～ 2026）
年間株価パフォーマンス
| 年 | パフォーマンス |
|---|---|
| 2026 (TTM) | -13.75% |
| 2025 | 54.26% |
| 2024 | 182.67% |
| 2023 | 21.69% |
| 2022 | -38.83% |
| 2021 | -32.39% |
| 2020 | 0.00% |
類似企業または競合の株価
| 企業 | 株価 | 変化率 1年% | 国 |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $766.95 | 9.01% |
CH
|
